Morphological and genetic screens reveal mechanisms of BiDAC-induced plasma membrane protein degradation
Author:
Affiliation:
1. Calico Life Sciences LLC
2. Calico Life Sciences, LLC
3. University of California, Merced
4. C4 Therapeutics Inc.
Abstract
The discovery of bifunctional degradation activating compounds (BiDACs) has led to the development of a new class of drugs that promote the clearance of their protein targets. BiDAC-induced ubiquitination is generally believed to direct cytosolic and nuclear proteins to proteolytic destruction by proteasomes. However, pathways that govern the degradation of other classes of BiDAC targets, such as integral membrane and intraorganellar proteins, have not been investigated in depth. In this study we used morphological profiling and CRISPR/Cas9 genetic screens to investigate the mechanisms by which BiDACs induce the degradation of plasma membrane receptor tyrosine kinases (RTKs) EGFR and Her2. We found that BiDAC-dependent ubiquitination triggers the trafficking of RTKs from the plasma membrane to lysosomes for degradation. Surprisingly, functional proteasomes were required for endocytosis of RTKs upstream of the lysosome. Additionally, our screen uncovered a non-canonical function of the lysosome-associated arginine/lysine transporter PQLC2 in EGFR degradation. Our data show that BiDACs may target proteins to proteolytic machinery other than the proteasome and motivate further investigation of mechanisms that govern the degradation of diverse classes of BiDAC targets.
Publisher
Research Square Platform LLC
Reference43 articles.
1. Antibodies directed against receptor tyrosine kinases;FAUVEL B;mAbs,2014
2. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020);Huang L;J Hematol Oncol J Hematol Oncol,2020
3. Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy;Pottier C;Cancers,2020
4. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface;Diwanji D;Nature,2021
5. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth;Agus DB;Cancer Cell,2002
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3